Pancreatic Neoplasms
Neoplasms
Neoplasms, Cystic, Mucinous, and Serous
Encyclopedias as Topic
Urogenital System
Genitalia, Female
Cyclin E in human cancers. (1/150)
Regulators of the cell cycle such as cyclin E play an important part in neoplasia. The cyclin E protein forms a partnership with a specific protein kinase. This complex phosphorylates key substrates to initiate DNA synthesis. Cyclin-dependent kinase inhibitors (CKIs) are able to suppress the activity of cyclin E. Various substances (including proteins produced by oncogenic viruses) affect cyclin E directly or indirectly through an interaction with CKIs. These interactions are important in elucidating the mechanisms of neoplasia. They may also provide prognostic information in a wide range of common cancers. Cyclin E may even be a target for treatment of cancers in the future. (+info)Rhabdomyosarcoma: an overview. (2/150)
Rhabdomyosarcoma (RMS) is a malignant tumor of mesenchymal origin thought to arise from cells committed to a skeletal muscle lineage. With approximately 250 cases diagnosed yearly in the United States, it is the third most common extracranial solid tumor of childhood after Wilms' tumor and neuroblastoma. Important epidemiologic, biologic, and therapeutic differences have been elucidated within the RMS family. Common sites of primary disease include the head and neck region, genitourinary tract, and extremities. A site-based tumor-nodes-metastasis staging system is being incorporated into use for assessing prognosis and assigning therapy in conjunction with the traditional surgicopathologic clinical grouping system. The development of intensive multimodality treatment protocols tested in large-scale international trials has resulted in significant improvements in outcome, especially for patients with local or locally extensive disease for whom a 60%-70% disease-free survival can be expected. Despite aggressive approaches incorporating surgery, dose-intensive combination chemotherapy, and radiation therapy, the outcome for patients with metastatic disease remains poor. Future challenges include the development of less toxic therapy for patients with localized disease and new approaches for patients with metastatic disease. (+info)Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. (3/150)
PURPOSE: The role of postchemotherapy surgery for patients with metastatic transitional cell carcinoma (TCC) is controversial. We retrospectively analyzed our experience with patients who underwent postchemotherapy surgery after methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) chemotherapy to assess an impact on long-term survival. PATIENTS AND METHODS: This report is based on the retrospective analysis of 203 patients with unresectable primary tumors or metastatic TCC, previously reported in five trials of M-VAC chemotherapy. Fifty patients underwent postchemotherapy surgery for suspected or known residual disease. Characteristics of patients selected for surgery, results of surgery, and the impact of surgery on survival were assessed. RESULTS: In 17 patients, no viable tumor was found at postchemotherapy surgery, pathologically confirming a complete response to chemotherapy. Three patients had unresectable residual TCC. In 30 patients, residual, viable TCC was completely resected, which resulted in a complete response to chemotherapy plus surgery. Ten (33%) of these 30 patients remained alive at 5 years, similar to results observed for patients who attained a complete response to chemotherapy alone (41%). Analysis by baseline extent of disease suggested that patients with unresectable primary tumors or with metastases restricted to lymph node sites were most likely to survive for 5 years. CONCLUSION: Postchemotherapy surgical resection of residual cancer may result in 5-year disease-free survival in some patients who would otherwise succumb to disease. Optimal candidates include patients whose prechemotherapy sites of disease are restricted to the primary or lymph node sites and who have a major response to chemotherapy. (+info)Pathways of O-glycan biosynthesis in cancer cells. (4/150)
Glycoproteins with O-glycosidically linked carbohydrate chains of complex structures and functions are found in secretions and on the cell surfaces of cancer cells. The structures of O-glycans are often unusual or abnormal in cancer, and greatly contribute to the phenotype and biology of cancer cells. Some of the mechanisms of changes in O-glycosylation pathways have been determined in cancer model systems. However, O-glycan biosynthesis is a complex process that is still poorly understood. The glycosyltransferases and sulfotransferases that synthesize O-glycans appear to exist as families of related enzymes of which individual members are expressed in a tissue- and growth-specific fashion. Studies of their regulation in cancer may reveal the connection between cancerous transformation and glycosylation which may help to understand and control the abnormal biology of tumor cells. Cancer diagnosis may be based on the appearance of certain glycosylated epitopes, and therapeutic avenues have been designed to attack cancer cells via their glycans. (+info)Critical evaluation of lymphocyte functions in urological cancer patients. (5/150)
One hundred three patients with varying stages of urological cancer (bladder, prostate, kidney) were investigated with regard to the following lymphocyte functions. T-cells were assessed numerically (E rosettes), their blastogenic response to phytohemagglutinin (pHA) was determined, and their cytotoxic potential against heterologous target cells in short-term presence of PHA (e.i., PHA-dependent cellular cytotoxocity) was evaluated. Similarly, B cells were numerically assessed (EA rosettes), and their function was evaluated by antibody-dependent cellular cytotoxicity against antibody-coated deterologous target cells. The data on cancer patients, divided on the basis of extent of disease and prior radiation therapy, were compared to those of normal young and age-matched controls. Our investigations emphasize the importance of the following factors: (a) comparison of data with age-matched controls, since several lymphocyte functions appear to change with age; (b) use of multiple controls to compensate for the inherent variability found in certain tests; (c) minimized contamination by nonlymphoid cells in the purified cell preparation; and (d) the influence of certain treatment regimens (radiation, chemotherapy, etc.) on the results. Radiotherapy significantly depressed T-cell number with a depression of PHA blastogenic responses as well as PHA-dependent cellular cytotoxicity. When all of these conditions were taken into account, the urological cancer patients as a group were found to have a lower proportional value of E rosettes (T-cells) and a reduced PHA blastogenic responsiveness. Certain cancer patients displayed an elevated PHA-dependent cellular cytotoxicity as compared to age-matched controls, which may indicate the presence of activated cells in the presence of tumors. With this identification of a group of cancer patients with markedly depressed E rosette values and PHA responsiveness, it will now be possible to follow them clinically in comparison with a group of cancer patients with normal T-cell functions. (+info)Correlations among cutaneous reactivity to DNCB, PHA-induced lymphocyte blastogenesis and peripheral blood E rosettes. (6/150)
Comparisons of the results obtained in a study of fifty-two patients with genitourinary malignancies using three assays to monitor the thymus-dependent immune system (delayed cutaneous hypersensitivity to DNCB, PHA-induced lymphocyte blastogenesis, and peripheral blood E rosette-forming lymphocyte counts) yielded statistically significant positive correlations between the DNCB and PHA assays in twenty-one of twenty-eight instances, the DNCB and E rosette assays in thirteen of sixteen instances, the PHA and E rosette assays in twenty-eight of thirty-six instances, and among the DNCB, PHA and E rosette assays in ten of fourteen instances. The results suggest that both PHA-stimulated lymphocyte blastogenesis and peripheral blood E rosette-forming lymphocyte levels provide meaningful in vitro correlates of cell-mediated immunity. (+info)Intestinal failure after surgery for complicated radiation enteritis. (7/150)
Between 1983 and 1997, a total of 16 patients were referred to a tertiary Intestinal Failure Unit (IFU) following surgery elsewhere for complications of radiation enteritis. Eleven were female with a mean age of 43 years (range 21-71 years) and the most common primary site of malignancy was genitourinary (n = 13). Patients had undergone an average of two laparotomies (range 1-7 laparotomies) for complications of radiation enteritis prior to transfer to the IFU. On admission, the principal problem in eight patients was persisting intestinal fistulation, four patients had continuing intestinal obstruction and four had the short bowel syndrome after extensive intestinal resection. Only one patient had evidence of residual malignancy; this patient with short bowel syndrome was allowed home without invasive therapy. Of the remaining 15 patients, 12 required an abdominal surgical procedure, while three were discharged without further surgery after training for home parenteral nutrition (HPN). Following abdominal surgery, five patients died in hospital, but the remaining seven patients went home alive--including two further patients on HPN. Overall, of the 15 patients referred with intestinal failure after surgery for complications of radiation enteritis and actively treated, one-third died in hospital and a further third required institution of HPN before being able to be discharged home. (+info)Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. (8/150)
BACKGROUND: The length of time after an episode of venous thromboembolism during which the risk of newly diagnosed cancer is increased is not known, and whether vitamin K antagonists have an antineoplastic effect is controversial. METHODS: In a prospective, randomized study of the duration of oral anticoagulation (six weeks or six months) after a first episode of venous thromboembolism, patients were questioned annually about any newly diagnosed cancer. After a mean follow-up of 8.1 years, we used the Swedish Cancer Registry to identify all diagnoses of cancer and causes of death in the study population. The observed numbers of cases of cancer were compared with expected numbers based on national incidence rates, and the standardized incidence ratios were calculated. RESULTS: A first cancer was diagnosed in 111 of 854 patients (13.0 percent) during follow-up. The standardized incidence ratio for newly diagnosed cancer was 3.4 (95 percent confidence interval, 2.2 to 4.6) during the first year after the thromboembolic event and remained between 1.3 and 2.2 for the following five years. Cancer was diagnosed in 66 of 419 patients (15.8 percent) who were treated for six weeks with oral anticoagulants, as compared with 45 of 435 patients (10.3 percent) who were treated for six months (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.4). The difference was mainly due to the occurrence of new urogenital cancers, of which there were 28 cases in the six-week group (6.7 percent) and 12 cases in the six-month group (2.8 percent) (odds ratio, 2.5; 95 percent confidence interval, 1.3 to 5.0). The difference in the incidence of cancer between the treatment groups became evident only after two years of follow-up, and it remained significant after adjustment for sex, age, and whether the thromboembolism was idiopathic or nonidiopathic. Older age at the time of the venous thrombosis and an idiopathic thromboembolism were also independent risk factors for a diagnosis of cancer. No difference in the incidence of cancer-related deaths was detected. CONCLUSIONS: The risk of newly diagnosed cancer after a first episode of venous thromboembolism is elevated during at least the following two years. Subsequently, the risk seems to be lower among patients treated with oral anticoagulants for six months than among those treated for six weeks. (+info)Urogenital neoplasms refer to abnormal growths or tumors that occur in the urinary and genital organs. These can include various types of cancer, such as bladder cancer, kidney cancer, prostate cancer, testicular cancer, cervical cancer, ovarian cancer, and others. Some urogenital neoplasms may be benign (non-cancerous), while others are malignant (cancerous) and can spread to other parts of the body.
The term "urogenital" refers to the combined urinary and genital systems in the human body. The urinary system includes the kidneys, ureters, bladder, and urethra, which are responsible for filtering waste from the blood and eliminating it as urine. The genital system includes the reproductive organs such as the ovaries, fallopian tubes, uterus, vagina, prostate gland, testicles, and penis.
Urogenital neoplasms can cause various symptoms depending on their location and size. Common symptoms include blood in urine, pain during urination, difficulty urinating, abnormal discharge, lumps or swelling in the genital area, and unexplained weight loss. If you experience any of these symptoms, it is important to consult a healthcare professional for further evaluation and treatment.
Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.
Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.
Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.
There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.
Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.
Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.
Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.
Neoplasms: Neoplasms refer to abnormal growths of tissue that can be benign (non-cancerous) or malignant (cancerous). They occur when the normal control mechanisms that regulate cell growth and division are disrupted, leading to uncontrolled cell proliferation.
Cystic Neoplasms: Cystic neoplasms are tumors that contain fluid-filled sacs or cysts. These tumors can be benign or malignant and can occur in various organs of the body, including the pancreas, ovary, and liver.
Mucinous Neoplasms: Mucinous neoplasms are a type of cystic neoplasm that is characterized by the production of mucin, a gel-like substance produced by certain types of cells. These tumors can occur in various organs, including the ovary, pancreas, and colon. Mucinous neoplasms can be benign or malignant, and malignant forms are often aggressive and have a poor prognosis.
Serous Neoplasms: Serous neoplasms are another type of cystic neoplasm that is characterized by the production of serous fluid, which is a thin, watery fluid. These tumors commonly occur in the ovary and can be benign or malignant. Malignant serous neoplasms are often aggressive and have a poor prognosis.
In summary, neoplasms refer to abnormal tissue growths that can be benign or malignant. Cystic neoplasms contain fluid-filled sacs and can occur in various organs of the body. Mucinous neoplasms produce a gel-like substance called mucin and can also occur in various organs, while serous neoplasms produce thin, watery fluid and commonly occur in the ovary. Both mucinous and serous neoplasms can be benign or malignant, with malignant forms often being aggressive and having a poor prognosis.
Vaginal neoplasms refer to abnormal growths or tumors in the vagina. These growths can be benign (non-cancerous) or malignant (cancerous). The two main types of vaginal neoplasms are:
1. Vaginal intraepithelial neoplasia (VAIN): This is a condition where the cells on the inner lining of the vagina become abnormal but have not invaded deeper tissues. VAIN can be low-grade or high-grade, depending on the severity of the cell changes.
2. Vaginal cancer: This is a malignant tumor that arises from the cells in the vagina. The two main types of vaginal cancer are squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma is the most common type, accounting for about 85% of all cases.
Risk factors for vaginal neoplasms include human papillomavirus (HPV) infection, smoking, older age, history of cervical cancer or precancerous changes, and exposure to diethylstilbestrol (DES) in utero. Treatment options depend on the type, stage, and location of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.
An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.
The urogenital system is a part of the human body that includes the urinary and genital systems. The urinary system consists of the kidneys, ureters, bladder, and urethra, which work together to produce, store, and eliminate urine. On the other hand, the genital system, also known as the reproductive system, is responsible for the production, development, and reproduction of offspring. In males, this includes the testes, epididymis, vas deferens, seminal vesicles, prostate gland, bulbourethral glands, and penis. In females, it includes the ovaries, fallopian tubes, uterus, vagina, mammary glands, and external genitalia.
The urogenital system is closely related anatomically and functionally. For example, in males, the urethra serves as a shared conduit for both urine and semen, while in females, the urethra and vagina are separate but adjacent structures. Additionally, some organs, such as the prostate gland in males and the Skene's glands in females, have functions that overlap between the urinary and genital systems.
Disorders of the urogenital system can affect both the urinary and reproductive functions, leading to a range of symptoms such as pain, discomfort, infection, and difficulty with urination or sexual activity. Proper care and maintenance of the urogenital system are essential for overall health and well-being.
Vulvar neoplasms refer to abnormal growths or tumors in the vulvar region, which is the exterior female genital area including the mons pubis, labia majora, labia minora, clitoris, and the vaginal vestibule. These neoplasms can be benign (non-cancerous) or malignant (cancerous).
Benign vulvar neoplasms may include conditions such as vulvar cysts, fibromas, lipomas, or condylomas (genital warts). They are typically slow-growing and less likely to spread or invade surrounding tissues.
Malignant vulvar neoplasms, on the other hand, are cancers that can invade nearby tissues and potentially metastasize (spread) to distant parts of the body. The most common types of malignant vulvar neoplasms are squamous cell carcinoma, vulvar melanoma, and adenocarcinoma.
Early detection and treatment of vulvar neoplasms are essential for improving prognosis and reducing the risk of complications or recurrence. Regular gynecological examinations, self-examinations, and prompt attention to any unusual symptoms or changes in the vulvar area can help ensure timely diagnosis and management.
Female genitalia refer to the reproductive and sexual organs located in the female pelvic region. They are primarily involved in reproduction, menstruation, and sexual activity. The external female genitalia, also known as the vulva, include the mons pubis, labia majora, labia minora, clitoris, and the external openings of the urethra and vagina. The internal female genitalia consist of the vagina, cervix, uterus, fallopian tubes, and ovaries. These structures work together to facilitate menstruation, fertilization, pregnancy, and childbirth.
Genitalia, also known as the genitals, refer to the reproductive organs located in the pelvic region. In males, these include the penis and testicles, while in females, they consist of the vulva, vagina, clitoris, and ovaries. Genitalia are essential for sexual reproduction and can also be associated with various medical conditions, such as infections, injuries, or congenital abnormalities.
Urogenital neoplasm
Gonadal tissue neoplasm
List of MeSH codes (C13)
List of diseases (U)
Human skin
Muir-Torre syndrome
Mycoplasma genitalium
List of MeSH codes
PAX8
Testicular sarcoidosis
Urethral cancer
GATA2 deficiency
Accessory spleen
Clonally transmissible cancer
Seminal vesicles
Oligospermia
Uterus
Spermatocele
Small intestine
Glossary of medicine
Infantile hemangioma
Testicle
Male infertility
Bladder cancer
Urogenital neoplasm - Wikipedia
Comparison of TRAM versus DIEP flap in total vaginal reconstruction after pelvic exenteration
Glatopa (glatiramer acetate Injection): Uses, Dosage, Side Effects, Interactions, Warning
Advanced Search Results - Public Health Image Library(PHIL)
Portal Regional da BVS
DailyMed - ZOLADEX- goserelin implant
Lupron, Eligard (leuprolide) dosing, indications, interactions, adverse effects, and more
UroToday
BVS Brasil
DeCS
Hereditary Breast and Ovarian Cancer Syndrome | Profiles RNS
Urogenital Squamous Cell Carcinoma: Practice Essentials, Pathophysiology of Penile SCC, Pathophysiology of Prostatic SCC
Gestational Trophoblastic Neoplasms | Harvard Catalyst Profiles | Harvard Catalyst
Neoplasms by Site - Ontology Report - Rat Genome Database
ICTRP Search Portal
Neoplasm staging. Medical search. Definitions
The occurrence of metronidazole-induced encephalopathy in cancer patients: A hospital-based retrospective study - 指紋 -...
Search Results for Minimally Invasive Surgery.
Urinary Bladder Neoplasms | Palmetto Profiles
Kevin Li-Chun Hsieh - 研究成果 - 臺北醫學大學
Ureteral Neoplasms | Profiles RNS
Uterine Cervical Neoplasms | Profiles RNS
Copaxone, Glatopa (glatiramer) dosing, indications, interactions, adverse effects, and more.
HPV Infection in Male | Abdominal Key
HuGE Navigator|Genopedia|PHGKB
Researchers interested in Radiotherapy, Intensity-Modulated | Yale School of Medicine
Urology | Profiles RNS
DailyMed - SUMATRIPTAN SUCCINATE tablet
Mass General - Division of Clinical Research
Carcinoma2
- Among malignant neoplasms of the penis, squamous cell carcinoma (SCC) is the most common. (medscape.com)
- Carcinoma in situ of the prostate is classified to code 233.4, and a benign neoplasm of the prostate goes to code 222.2. (prostateprohelp.com)
Metastasis1
- Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms . (lookformedical.com)
Tumors1
- Metastatic disease to the pancreas is an exceptionally rare occurrence, more so when considering occult primary tumors of urogenital origin. (hcahealthcare.com)
Malignant neoplasms1
- What does screening for malignant neoplasms of prostate mean? (prostateprohelp.com)
Epithelial1
- SCC of the prostate is a rare malignant epithelial neoplasm arising in the prostate, with squamous differentiation of the neoplastic cells. (medscape.com)
Histological type1
- The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. (lookformedical.com)
Prostate4
- C61 is a billable code used to specify a medical diagnosis of malignant neoplasm of prostate. (prostateprohelp.com)
- One may also ask, what does c61 malignant neoplasm of prostate mean? (prostateprohelp.com)
- The overall prognosis of a patient with Malignant Neoplasm of the Prostate depends on the age, overall health of the patient, and stage of the disease process. (prostateprohelp.com)
- Since this is a slow growing tumor, even if the diagnosis is made a bit late with adequate treatments the prognosis for the patient overall is fair to good post treatment of Malignant Neoplasm of the Prostate. (prostateprohelp.com)
Headings1
- Gestational Trophoblastic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (harvard.edu)
Organs2
- Urogenital system - The urogenital system includes the sex organs, the urinary system, and the excretion of vertebrates. (en-academic.com)
- urogenital malformation - Defect in the organs or tissues of the urinary system or in the sex organs (genitals). (en-academic.com)
Tumor3
- A urogenital neoplasm is a tumor of the urogenital system. (wikipedia.org)
- 10 ICD9 = ICDO = OMIM = MedlinePlus = eMedicineSubj = eMedicineTopic = MeshID = D014565A urogenital neoplasm is a tumor of the urogenital system. (en-academic.com)
- A malignant neoplasm is a cancerous tumor , an abnormal growth that can grow uncontrolled and spread to other parts of the body. (prostateprohelp.com)
Profiles2
- This graph shows the total number of publications written about "Gestational Trophoblastic Neoplasms" by people in Harvard Catalyst Profiles by year, and whether "Gestational Trophoblastic Neoplasms" was a major or minor topic of these publication. (harvard.edu)
- Below are the most recent publications written about "Gestational Trophoblastic Neoplasms" by people in Profiles. (harvard.edu)
Female1
- Congenital structural abnormalities of the UROGENITAL SYSTEM in either the male or the female. (nih.gov)
System1
- Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. (lookformedical.com)
Invasion1
- These neoplasms have varying propensities for invasion and spread. (harvard.edu)
Head2
- ENETS has a long experience in neuroendocrine neoplasms (NENs) and has a high level of expertise and multi-center co-operation resulting from its networking with ENETS Centers of Excellence (CoE) for gastroenteropancreatic (GEP), thoracic, head and neck, and urogenital NENs in Europe as well as non-European countries, such as the USA and Australia. (enets.org)
- Head and neck, thoracic, GEP and urogenital NEN patients seen in centers from the 1 January 2010 onwards are eligible to be enrolled. (enets.org)
Terms1
- Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. (lookformedical.com)
Diseases3
- One hundred ninety-six salivary metabolites were mapped into 49 metabolic pathways and connected with human metabolic diseases, central nervous system diseases, and neoplasms. (nih.gov)
- Urology deals with the study of the urinary system and related to it human reproductive system, the physiological and pathological processes occurring in them, the diagnosis, prevention and treatment of diseases of the urogenital organs (urethra, bladder, ureters, kidneys, male genital organs). (german-medicalgroup.com)
- Urogenital diseases are far from being harmless. (german-medicalgroup.com)
Cancer3
- We integrated all the eligible studies and investigated whether the TNF-α 308G/A polymorphism correlates with urogenital cancer risk. (nih.gov)
- PubMed, EMBASE, Web of Science, the Cochrane Library, the Chinese Biomedical Literature Database, and the Wanfang Database were searched for all case-control studies on the relationship between the TNF-α 308G/A polymorphism and susceptibility to urogenital cancer between January 1994 and January 2015. (nih.gov)
- Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female. (bvsalud.org)
Uterine Neoplasms2
- This graph shows the total number of publications written about "Uterine Neoplasms" by people in this website by year, and whether "Uterine Neoplasms" was a major or minor topic of these publications. (sdsu.edu)
- Below are the most recent publications written about "Uterine Neoplasms" by people in Profiles. (sdsu.edu)
Pathology1
- Urologists are engaged in the treatment and prevention of the pathology of male and female urogenital systems. (german-medicalgroup.com)
Benign3
- A comprehensive review and update of histopathology with discussion of clinical significance of benign and malignant tumors of the urogenital tract will be provided. (ordensklinikum.at)
- CONCLUSIONS: Neoplasia is not uncommon in the chimpanzee, is generally benign, and occurs primarily in the urogenital system in females. (anthropogeny.org)
- Angiomyolipoma is a benign neoplasm of mesenchymal origin that primarily consists of proliferating adipocytes, smooth muscle cells, vascular structures, and macrophages. (symptoma.com)
Tract1
- 29. [CEA determination in urogenital tract neoplasms]. (nih.gov)
Infections1
- The most common pathologies of male urogenital system are inflammatory processes (orchitis and epididymitis, urethritis, balanoposthitis, prostatitis, cystitis), prostate adenoma and genital infections. (german-medicalgroup.com)
Metastatic1
- Included in this category are primary and metastatic nervous system neoplasms. (uchicago.edu)
Bladder1
- The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms. (lookformedical.com)
Prostatic1
- It is used to treat hypogonadism, premature menopause, and prostatic neoplasms in the USA. (pharmakb.com)
Mesh2
- Urethral Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (uams.edu)
- Urologic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (musc.edu)
Gynaecological1
- Urogenital fistulas are a known but uncommon complication of gynaecological surgery, especially those involving a malignant process. (annals.edu.sg)